A Covid-19 vaccine maker's IPO plans

CureVac, a German biotech with a coronavirus vaccine in clinical development, has filed for a $100 million IPO. The company received clearance to begin human trials of its mRNA-based vaccine in June, and expects results by the fourth quarter of this year. 

The German government said it would invest about $338.5 million for a 23% stake in CureVac. Other investors include the Qatar Investment Authority and GlaxoSmithKline. GSK, in announcing the deal last week, said CureVac's platform would complement the pharma giant's own mRNA vaccine technology.